Credo Life Sciences Private Limited - Due diligence report

A 360° intelligence report on Credo Life Sciences: trust score, financial health, credit view, compliance, directors, growth and distress si…

2014-07-03 Shaikpet, Telangana Active Unlisted Active Compliant
Share
CL Credo Life Sciences Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Credo Life Sciences — 360° Intelligence Report

Generated from MCA filings & public records
90/100
Trust Score
Low Risk

Credo Life Sciences is assessed as Low Risk with a Trust Score of 90/100. Credo Life Sciences is an active private limited indian non-government company incorporated in 2014, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Credo Life Sciences Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
90/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
88/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
85/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
60/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 60/100 Moderate
  • Open charges exceed net worth - secured lenders rank ahead.
  • Profitable - internal accruals available.
  • Externally credit-rated (BB).

Charges position: 4 open (32.48 cr) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Indian Bank3 48.0 cr
Hdfc Bank Limited1 48.0 cr
Compliance Score: 88/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
KANDRU MADHAVARAO 01234567 Director 01/04/2018 6 yrs Approved
SIVA RAMA PRASAD ALURU 01234567 Director 01/04/2018 6 yrs Approved
ALURU VAMSI KRISHNA 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2024 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
8 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Key managerial personnel: SIVA RAMA PRASAD ALURU (Managing Director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +38% over 4 year(s).
Latest year revenue grew 1.42.
Profit expanded 2.1x year-on-year.
Net margin improved to 24%.
EPFO headcount growing - hiring signal.
Operating for 12+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
4 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence89/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment74/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 4 open charge(s) of 32.48 cr already registered.
  • Compliance record supports lending.
Investor view90/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 5 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
19 Feb 2025
Charge created
Indian Bank - 1.98 cr
18 Nov 2024
Charge created
Indian Bank - 2.15 cr
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
03 Jan 2023
Charge created
Hdfc Bank Limited - 35.00 Lakh
06 Jul 2021
Director ceased
Venkata Narayana Reddy Konda
25 Jun 2021
Securities allotted
2000000 Equity Shares - 2.00 cr raised
27 Jul 2017
Securities allotted
340000 Equity Shares - 34.00 Lakh raised
09 Jun 2017
Securities allotted
2160000 Equity Shares - 2.16 cr raised
22 Feb 2017
Securities allotted
710000 Equity Shares - 71.00 Lakh raised
31 Oct 2016
Charge created
Indian Bank - 28.00 cr
11 Jul 2016
Securities allotted
1570000 Equity Shares - 1.57 cr raised
29 Mar 2016
Securities allotted
2645000 Equity Shares - 2.65 cr raised
18 Sep 2015
Director ceased
KANDRU MADHAVARAO
06 Jul 2015
Securities allotted
900000.00 Equity Shares - 90.00 Lakh raised
10

Key Observations

Auto-generated from the data above
Revenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of BB from Icra.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 8 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Imerys Vizag Private Limited U26933AP2011PTC118564 Anakapalle, Andhra Pradesh, India
Shivalik Remedies Private Limited U24232DL2005PTC133923 New Delhi, Delhi, India
Abhilash Chemicals And Pharmaceuticals Private Limited U24294TN1994PTC026936 Madurai North, Tamil Nadu, India
Champion U24233MH2010PTC209146 Mumbai, Maharashtra, India
Pharma Impex Laboratories Pvt Ltd U24231WB1977PTC031208 Kolkata, West Bengal, India
Poly Plast Chemi-Plants(India) Private Limited U29299MH1991PTC060175 Mumbai, Maharashtra, India
Pelltechhealthcare U24230MH2003PTC141586 Thane, Maharashtra, India
Consern Pharma U24232PB2001PLC024715 Ludhiana, Punjab, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Credo Life Sciences before audits and certifications: compliance score 88/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Credo Life Sciences: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 60/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Credo Life Sciences - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 90/100, distress signals and MSME payment-delay disclosures - know whether Credo Life Sciences pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Credo Life Sciences - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Credo Life Sciences an active company?

Credo Life Sciences has MCA status “Active” with a compliance score of 88/100 (Low Risk).

Is Credo Life Sciences financially healthy?

Credo Life Sciences has a Financial Health Score of 85/100 (Low Risk) based on its filed financial statements.

Should I do business with Credo Life Sciences?

Its overall Trust Score is 90/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Credo Life Sciences?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.

Does Credo Life Sciences have loans or charges against its assets?

4 open charge(s) are registered against its assets.

Is Credo Life Sciences up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 88/100 (Low Risk).

Is it risky to lend to Credo Life Sciences?

Its Credit Risk Score is 60/100 (Moderate). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.